162 related articles for article (PubMed ID: 31445985)
1. Demographic and health-related predictors of proton pump inhibitor (PPI) use and association with chronic kidney disease (CKD) stage in NHANES population.
Devraj R; Deshpande M
Res Social Adm Pharm; 2020 Jun; 16(6):776-782. PubMed ID: 31445985
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
3. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
4. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study.
Liabeuf S; Lambert O; Metzger M; Hamroun A; Laville M; Laville SM; Frimat L; Pecoits-Filho R; Fouque D; Massy ZA; Jacquelinet C; Stengel B;
Br J Clin Pharmacol; 2021 Jul; 87(7):2967-2976. PubMed ID: 33368448
[TBL] [Abstract][Full Text] [Related]
5. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study.
Kim SG; Cho JM; Han K; Joo KW; Lee S; Kim Y; Cho S; Huh H; Kim M; Kang E; Kim DK; Park S
BMJ Open; 2024 Jan; 14(1):e078032. PubMed ID: 38286693
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease.
Arora P; Gupta A; Golzy M; Patel N; Carter RL; Jalal K; Lohr JW
BMC Nephrol; 2016 Aug; 17(1):112. PubMed ID: 27487959
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis.
Grant CH; Gillis KA; Lees JS; Traynor JP; Mark PB; Stevens KI
QJM; 2019 Nov; 112(11):835-840. PubMed ID: 31251364
[TBL] [Abstract][Full Text] [Related]
8. Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort.
Rodríguez-Poncelas A; Barceló MA; Saez M; Coll-de-Tuero G
PLoS One; 2018; 13(10):e0204231. PubMed ID: 30332411
[TBL] [Abstract][Full Text] [Related]
9. Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a nationwide database-derived case-controlled study.
Hung SC; Liao KF; Hung HC; Lin CL; Lai SW; Lee PC; Hung SR
Fam Pract; 2018 Mar; 35(2):166-171. PubMed ID: 29045621
[TBL] [Abstract][Full Text] [Related]
10. Association of Proton Pump Inhibitor Use With Serum Biomarkers of Inflammation, Insulin Resistance, Cardiovascular Risk, and Renal Function.
Austin GL; Weiskopf JR; Czwornog JL
J Clin Gastroenterol; 2018 Sep; 52(8):691-695. PubMed ID: 29099466
[TBL] [Abstract][Full Text] [Related]
11. Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients.
Lee HJ; Lee H; Oh SH; Park J; Park S; Jeon JS; Noh H; Han DC; Kwon SH
PLoS One; 2018; 13(9):e0203878. PubMed ID: 30212538
[TBL] [Abstract][Full Text] [Related]
12. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
[TBL] [Abstract][Full Text] [Related]
13. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.
Klatte DCF; Gasparini A; Xu H; de Deco P; Trevisan M; Johansson ALV; Wettermark B; Ärnlöv J; Janmaat CJ; Lindholm B; Dekker FW; Coresh J; Grams ME; Carrero JJ
Gastroenterology; 2017 Sep; 153(3):702-710. PubMed ID: 28583827
[TBL] [Abstract][Full Text] [Related]
14. Use of Potentially Nephrotoxic Medications by U.S. Adults with Chronic Kidney Disease: NHANES, 2011-2016.
Kurani S; Jeffery MM; Thorsteinsdottir B; Hickson LJ; Barreto EF; Haag J; Giblon R; Shah ND; McCoy RG
J Gen Intern Med; 2020 Apr; 35(4):1092-1101. PubMed ID: 31792867
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease.
Hughes J; Y Y Chiu D; Kalra PA; Green D
PLoS One; 2018; 13(5):e0197400. PubMed ID: 29799851
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system.
Wu B; Li D; Xu T; Luo M; He Z; Li Y
Sci Rep; 2021 Feb; 11(1):3690. PubMed ID: 33574396
[TBL] [Abstract][Full Text] [Related]
17. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
Xie Y; Bowe B; Li T; Xian H; Balasubramanian S; Al-Aly Z
J Am Soc Nephrol; 2016 Oct; 27(10):3153-3163. PubMed ID: 27080976
[TBL] [Abstract][Full Text] [Related]
18. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression.
Cholin L; Ashour T; Mehdi A; Taliercio JJ; Daou R; Arrigain S; Schold JD; Thomas G; Nally J; Nakhoul NL; Nakhoul GN
BMC Nephrol; 2021 Jul; 22(1):264. PubMed ID: 34266395
[TBL] [Abstract][Full Text] [Related]
19. Associations between Proton-Pump Inhibitor Usage, Allergy, and Asthma: An Analysis of NHANES 2005-2006.
Yu R; Wang X; Wang H; Lu X; Yang B
Int Arch Allergy Immunol; 2024; 185(6):519-526. PubMed ID: 38432205
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
